Sipuleucel-T in management of favorable-risk prostate cancer: the ProVent trial

At the end of last year, Dendreon announced that the Phase III ProVent trial of sipuelucel-T (Provenge) in the treatment of men with relatively lower-risk forms of prostate cancer (as compared to active surveillance) had been fully enrolled ahead of schedule. … READ MORE …

Should SBRT be THE preferred treatment for intermediate-risk prostate cancer?

Last year, the American Society of Radiation Oncologists (ASTRO) looked at the available evidence comparing hypofractionated radiotherapy (either 60 Gy in 20 treatments or 70 Gy in 28 treatments) to standard fractionation (78 to 82 Gy in 40 to 44 treatments), and found it was at least as good in terms of oncological outcomes and toxicity. … READ MORE …

“Long-term” data on FLA in the treatment of localized prostate cancer

An important new paper in the Journal of Vascular and Interventional Radiology has just provided us with the first large set of data on the outcomes of men with prostate cancer treated with focal laser ablation (FLA). … READ MORE …

Focal HIFU in treatment of (largely) intermediate-risk prostate cancer

In addition to the French data previously referred to on this site, data from another, much larger cohort of men treated with focal, high-intensity focused ultrasound (focal HIFU) are also to be presented at the upcoming annual meeting of the American Urological Association. … READ MORE …

Toxicity higher with hypofractionation in Dutch radiotherapy trial using 3D-CRT

A Dutch research group has published the toxicity outcomes of a randomized clinical trial (HYPRO) designed to test whether a hypofractionated external beam (EBRT) regimen compared to conventional fractionation. They will report on the oncological outcomes at a later date. … READ MORE …

Neoadjuvant chemotherapy prior to surgery in higher-risk patients

A combined Russian and German research team has provided some interesting preliminary information on the use of neoadjuvant, low-dose docetaxel-based chemotherapy in treatment of intermediate- and high-risk patients prior to radical prostatectomy. … READ MORE …

The potential of low-dose enzalutamide in intermediate-risk prostate cancer

A case study report in the journal Research and Reports in Urology (which is not exactly a widely read publication) addresses the treatment of an elderly man with low-risk prostate cancer with low-dose enzalutamide as a form of first-line therapy. … READ MORE …

SBRT in men with intermediate-risk, localized prostate cancer

Data reported by Meier et al. and presented at the recent annual meeting of the American Society for Radiation Oncology (ASTRO) provide some early guidance on the efficacy and safety of sterotactic body radiation therapy (SBRT) in treatment of men with intermediate-risk, localized prostate cancer. … READ MORE …

Relative cost-effectiveness of SBRT and IMRT in treatment of localized prostate cancer

A new paper in the Journal of Oncology Practice has attempted to compare the cost-effectiveness of stereotactic body radiation therapy (SBRT) to that of intensity-modulated radiation therapy (IMRT) in the treatment of men with low- to intermediate-risk prostate cancer. … READ MORE …

Initial study of single-dose HDR brachytherapy for localized prostate cancer

In the past, high-dose-rate (HDR) brachytherapy has been used alone or (more commonly) in combination with external beam radiation therapy (EBRT) for the treatment of localized prostate cancer. However, when used alone, it has been necessary to treat the patient with several sessions of HDR brachytherapy. … READ MORE …

Active surveillance and intermediate-risk prostate cancer

A Reuters report on a forthcoming study in the Journal of Clinical Oncology has suggested that some men with intermediate-risk prostate cancer may be able to safely defer treatment in favor of monitoring the disease over time (through active surveillance) for a period of at least 4 years. … READ MORE …

Prostate cancer news reports: Wednesday, May 5, 2010

In today’s news reports we address data from studies dealing with:

  • Cancer risk in young Korean males with an elevated PSA level
  • Mushroom-based supplements in the treatment of prostate cancer
  • Outcomes after brachytherapy in intermediate-risk Canadian patients
  • Traumatic stress among African American prostate cancer patients … READ MORE …